



## Canadian spotlight 17.1: Key additions from the first half of May 2022

In the first half of May, contributing Canadian evidence-synthesis teams have shared with us six newly completed evidence syntheses which are listed in the table below. From the COVID-END taxonomy, these syntheses provided insight focused on public-health measures (n=4) and clinical management (n=2).

Taxonomy section	Title	Type of product	Date of last search (and publication)	Evidence synthesis team
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">What is the effectiveness of available COVID-19 vaccines for variants of concern in adults over time frames up to 120 days?</a>	Update to a living evidence synthesis	2022-05-12 (published 2022-05-13)	Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">What is the effectiveness of available COVID-19 vaccines for children and adolescents, including variants of concern?</a>	Update to a living evidence synthesis	2022-05-09 (published 2022-05-11)	Faculty of Medicine, University of Antioquia & Health Information Research Unit, McMaster University
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	<a href="#">Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination?</a>	Rapid review	2022-05-02 (published 2022-05-10)	Saskatchewan Health Authority; University of Saskatchewan; Saskatchewan Health Authority Council
<ul style="list-style-type: none"> <li>Public-health measures</li> </ul>	Evidence brief on attitudes and acceptances of COVID-19 booster doses: Update 1 (For those interested in accessing the full copy of the rapid review, please contact <a href="mailto:phac.ocsoevidence-">phac.ocsoevidence-</a>	Rapid review	2022-05-01 (published 2022-05-01)	Emerging Science Group, Public Health Agency of

	<a href="mailto:bcscdonneesprobantes.aspc@canada.ca">bcscdonneesprobantes.aspc@canada.ca</a>			Canada (PHAC)
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p>Evidence on the effectiveness and safety of ultraviolet germicidal irradiation technologies in reducing SARS-CoV-2 in the air of occupied rooms</p> <p>(For those interested in accessing the full copy of the rapid review, please contact <a href="mailto:phac.ocsoevidence-bcscdonneesprobantes.aspc@canada.ca">phac.ocsoevidence-bcscdonneesprobantes.aspc@canada.ca</a>)</p>	Rapid review	2022-03-18 (published 2022-03-18)	Emerging Science Group, Public Health Agency of Canada (PHAC)
<ul style="list-style-type: none"> <li>Clinical management</li> </ul>	<p><a href="#">Clinical classification and interventions for post-COVID-19 condition: A scoping review</a></p>	Scoping review	2021-12-20 (published 2022-05-06)	Canadian Agency for Drugs and Technologies in Health (CADTH)